SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 122.
  • 2
    Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 28596.
  • 3
    Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Jänicke F, Löning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol 1999; 189: 24550.
  • 4
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 16174.
  • 5
    Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 2002; 3: 93243.
  • 6
    Behrendt N, Rønne E, Danø K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem Hoppe Seyler 1995; 376: 26979.
  • 7
    Diel IJ, Kaufmann M, Costa SD, Holle R, Von Minckwitz G, Solomayer EF, Kaul S, Bastert G. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 165264.
  • 8
    Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999; 354: 197202.
  • 9
    Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CRM, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 52533.
  • 10
    Gerber B, Krause A, Müller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 2001; 19: 96071.
  • 11
    Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jäger W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001; 19: 366974.
  • 12
    Rønne E, Behrendt N, Ellis V, Ploug M, Danø K, Høyer-Hansen G. Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 1991; 288: 2336.
  • 13
    Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (irs) for immunohistochemical estrogen receptor detection (er-ica) in breast cancer tisssue. Pathologe 1987; 8: 13840.
  • 14
    Carriero MV, Franco P, Del Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 1994; 54: 544554.
  • 15
    Del Vecchio S, Stoppelli MP, Carriero MV, Fonti R, Massa O, Li PY, Botti G, Cerra M, D'Aiuto G, Esposito G, Salvatore M. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res 1993; 53: 3198206.
  • 16
    Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 1996; 77: 107988.
  • 17
    Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Müller M, Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997; 150: 123144.
  • 18
    Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. 2000. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology 2000; 36: 499504.
  • 19
    Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am J Pathol 2000; 157: 121927.
  • 20
    Pyke C, Græm N, Ralfkiær E, Rønne E, Høyer-Hansen G, Brünner N, Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993; 53: 19115.
  • 21
    Bianchi E, Cohen RL, Thor AT, Todd RF III, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 8616.
  • 22
    Kennedy S, Duffy MJ, Duggan C, Barnes C, Rafferty R, Kramer MD. Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Br J Cancer 1998; 77: 163841.
  • 23
    Hildenbrand R, Wolf G, Böhme B, Bleyl U, Steinborn A. Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue. J Leukoc Biol 1999; 66: 409.
  • 24
    Kim SJ, Shiba E, Taguchi T, Watanabe T, Tanji Y, Kimoto Y, Izukura M, Takai SI. Urokinase type plasminogen activator receptor is a novel prognostic factor in breast cancer. Anticancer Res 1997; 17: 13738.
  • 25
    Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996; 67: 4239.
  • 26
    Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, Harris AL. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. J Natl Cancer Inst 1997; 89: 10449.
  • 27
    Fisher JL, Field CL, Zhou H, Harris TL, Henderson MA, Choong PFM. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases: a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat 2000; 61: 112.
  • 28
    Tögel F, Datta C, Badbaran A, Kröger N, Renges H, Gieseking F, Jänicke F, Zander AR, Krüger W. Urokinase-like plasminogen activator receptor expression on disseminated breast cancer cells. J Hematother Stem Cell Res 2001; 10: 1415.
  • 29
    Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1995; 1: 10359.
  • 30
    Noack F, Helmecke D, Rosenberg R, Thorban S, Nekarda H, Fink U, Lewald J, Stich M, Schütze K, Harbeck N, Magdolen V, Graeff H, Schmitt M. CD87-positive tumor cells in bone marrow aspirates identified by confocal laser scanning fluorescence microscopy. Int J Oncol 1999; 15: 61723.
  • 31
    Yu W, Kim J, Ossowski L. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy. J Cell Biol 1997; 137: 76777.